AMENDMENTS TO THE CLAIMS

1-74. (Canceled)

75. (Previously presented) A method for treating a cancer disorder selected from the group consisting of melanoma, breast cancer, prostate cancer, lung cancer, pancreatic cancer, thyroid cancer, bladder cancer, colon cancer, liver cancer, myeloid leukemia, and villous colon adenoma in a human or animal subject, comprising administering to the human or animal subject a composition comprising an amount of a compound of the formula (I) effective to inhibit Raf kinase activity in a human or animal subject:



(I)

wherein, X_1 and X_2 are =N- or -NR_4-, provided that if X_1 is -NR_4-, then X_2 is =N-, or if X_2 is -NR_4-, then X_2 is =N-;

Y is O or S;

A_1 is substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, polycyclic aryl, polycyclic arylalkyl, heteroaryl, biaryl, heteroarylaryl, heteroarylheteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, biarylalkyl, or heteroarylarylalkyl;

A_2 is substituted or unsubstituted heteroaryl;

R1 is O or H, and R2 is NR5R6 or hydroxyl; or R1 is taken together with R2 to form a substituted or unsubstituted heterocycloalkyl or heteroaryl group; wherein, the dashed line represents a single or double bond;

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206 682 8100

R_3 is hydrogen, halogen, loweralkyl, or loweralkoxy;

R_4 is hydrogen, hydroxyl, alkylamino, dialkylamino or alkyl;

R_5 and R_6 are independently selected from hydrogen, and substituted or unsubstituted alkyl, alkoxyalkyl, aminoalkyl, amidoalkyl, acyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxyalkylheterocyclo, and heteroarylalkyl; or R_5 and R_6 are taken together to form substituted or unsubstituted heterocyclo or heteroaryl; and

R_7 is loweralkyl;

or a pharmaceutically acceptable salt, ester or prodrug thereof.

76. (Previously presented) The method of claim 75 which further comprises administering to the human or animal subject at least one additional agent for the treatment of cancer selected from irinotecan, topotecan, gemcitabine, 5-fluorouracil, leucovorin carboplatin, cisplatin, taxanes, tezacitabine, cyclophosphamide, vinca alkaloids, imatinib, anthracyclines, rituximab and trastuzumab.

77. (Canceled)

78. (Previously presented) A method for treating a Ras/mitogen-activated protein kinase signal pathway-mediated hormone dependent cancer disorder selected from the group consisting of breast cancer and prostate cancer in a human or animal subject, comprising administering to the human or animal subject a composition comprising an amount of a compound of the formula (I) effective to inhibit Raf kinase activity in a human or animal subject:



(I)

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

wherein, X_1 and X_2 are =N- or -NR_4-, provided that if X_1 is -NR_4-, then X_2 is =N-, or if X_2 is -NR_4-, then X_2 is =N-;

Y is O or S;

A_1 is substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, polycyclic aryl, polycyclic arylalkyl, heteroaryl, biaryl, heteroarylaryl, heteroarylheteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, biarylalkyl, or heteroarylarylalkyl;

A_2 is substituted or unsubstituted heteroaryl;

R_1 is O or H, and R_2 is NR_5R_6 or hydroxyl; or R_1 is taken together with R_2 to form a substituted or unsubstituted heterocycloalkyl or heteroaryl group; wherein, the dashed line represents a single or double bond;

R_3 is hydrogen, halogen, loweralkyl, or loweralkoxy;

R_4 is hydrogen, hydroxyl, alkylamino, dialkylamino or alkyl;

R_5 and R_6 are independently selected from hydrogen, and substituted or unsubstituted alkyl, alkoxyalkyl, aminoalkyl, amidoalkyl, acyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxyalkylheterocyclo, and heteroarylalkyl; or R_5 and R_6 are taken together to form substituted or unsubstituted heterocyclo or heteroaryl; and

R_7 is loweralkyl;

or a pharmaceutically acceptable salt, ester or prodrug thereof.

79. (Canceled)

80. (Previously presented) The method of claim 78 which further comprises administering to the human or animal subject at least one additional agent for the treatment of cancer selected from irinotecan, topotecan, gemcitabine, 5-fluorouracil, leucovorin carboplatin,

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

cisplatin, taxanes, tezacitabine, cyclophosphamide, vinca alkaloids, imatinib, anthracyclines, rituximab and trastuzumab.

81. (Canceled)

82. (Previously presented) A method for treating a Ras/mitogen-activated protein kinase signal pathway-mediated hematological cancer disorder in a human or animal subject, comprising administering to the human or animal subject a composition comprising an amount of a compound of the formula (I) effective to inhibit Raf kinase activity in a human or animal subject:



(I)

wherein, X_1 and X_2 are =N- or -NR_4-, provided that if X_1 is -NR_4-, then X_2 is =N-, or if X_2 is -NR_4-, then X_2 is =N-;

Y is O or S;

A_1 is substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, polycyclic aryl, polycyclic arylalkyl, heteroaryl, biaryl, heteroarylaryl, heteroarylheteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, biarylalkyl, or heteroarylarylalkyl;

A_2 is substituted or unsubstituted heteroaryl;

R_1 is O or H, and R_2 is NR_5 R_6 or hydroxyl; or R_1 is taken together with R_2 to form a substituted or unsubstituted heterocycloalkyl or heteroaryl group; wherein, the dashed line represents a single or double bond;

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

R_3 is hydrogen, halogen, loweralkyl, or loweralkoxy;

R_4 is hydrogen, hydroxyl, alkylamino, dialkylamino or alkyl;

R_5 and R_6 are independently selected from hydrogen, and substituted or unsubstituted alkyl, alkoxyalkyl, aminoalkyl, amidoalkyl, acyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxyalkylheterocyclo, and heteroarylalkyl; or R_5 and R_6 are taken together to form substituted or unsubstituted heterocyclo or heteroaryl; and

R_7 is loweralkyl;

or a pharmaceutically acceptable salt, ester or prodrug thereof.

83. (Previously presented) The method of claim 82 which further comprises administering to the human or animal subject at least one additional agent for the treatment of cancer selected from irinotecan, topotecan, gemcitabine, 5-fluorouracil, leucovorin carboplatin, cisplatin, taxanes, tezacitabine, cyclophosphamide, vinca alkaloids, imatinib, anthracyclines, rituximab and trastuzumab.

84-86. (Canceled)

87. (Currently amended) A method of any one of [claim] claims 75, 76, 78, 80, 82, or 83, wherein X_1 is NR_4 and X_2 is N in formula (I).

88. (Currently amended) A method of any one of [claim] claims 75, 76, 78, 80, 82, or 83, wherein R_4 in formula (I) is hydrogen or C_{1-6} alkyl.

89. (Previously presented) The method of claim 88, wherein R_4 in formula (I) is methyl.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

90. (Currently amended) A method of any one of [claim] claims 75, 76, 78, 80, 82, or 83, wherein Y in formula (I) is O.

91. (Currently amended) A method of any one of [claim] claims 75, 76, 78, 80, 82, or 83, wherein A_1 in formula (I) is substituted or unsubstituted C_{3-14} aryl.

92. (Previously presented) The method of claim 91, wherein A1 in formula (I) is selected from the group consisting of substituted or unsubstituted phenyl, pyridyl, pyrimidinyl, phenylalkyl, pyridylalkyl, pyrimidinylalkyl, heterocyclylcarbonylphenyl, heterocyclylphenyl, heterocyclylalkylphenyl, chlorophenyl, fluorophenyl, bromophenyl, iodophenyl, dihalophenyl, nitrophenyl, 4-bromophenyl, 4-chlorophenyl, alkylbenzoate, alkoxyphenyl, dialkoxyphenyl, dialkylphenyl, trialkylphenyl, thiophene, thiophene-2-carboxylate, alkylthiophenyl, trifluoromethylphenyl, acetylphenyl, sulfamoylphenyl, biphenyl, cyclohexylphenyl, phenyloxyphenyl, dialkylaminophenyl, alkylbromophenyl, alkylchlorophenyl, alkylfluorophenyl, trifluoromethylchlorophenyl, trifluoromethylbromophenyl, indenyl, 2,3-dihydroindenyl, tetralinyl, trifluorophenyl, (trifluoromethyl)thiophenyl, alkoxybiphenyl, morpholinyl, N-piperazinyl, N-morpholinylalkyl, piperazinylalkyl, cyclohexylalkyl, indolyl, 2,3-dihydroindolyl, 1-aceyt1-2,3-dihydroindolyl, cycloheptyl, bicyclo[2.2.1]hept-2-yl, hydroxyphenyl, hydroxyalkylphenyl, pyrrolidinyl, pyrrolidin-1-yl, pyrrolidin-1-ylalkyl, 4-amino(imino)methylphenyl, isoxazolyl, indazolyl, adamantyl, bicyclohexyl, quinuclidinyl, imidazolyl, benzimidazolyl, imidazolylphenyl, phenylimidazolyl, pthalamido, napthyl, benzophenone, anilinyl, anisolyl, quinolinyl, quinolinonyl, phenylsulfonyl, phenylalkylsulfonyl, 9H-flouren-1-yl, piperidin-1-yl, piperidin-1-ylalkyl, cyclopropyl, cyclopropylalkyl, pyrimidin-5-ylphenyl, quinolidinylphenyl, furanyl, furanylphenyl, N-methylpiperidin-4-yl, pyrrolidin-4-

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

ylpyridinyl, 4-diazepan-1-yl, hydroxypyrrolidn-1-yl, dialkylaminopyrrolidin-1-yl, 1,4'-bipiperidin-1'-yl, and (1,4'-bipiperidin-1'-ylcarbonyl)phenyl.

93. (Currently amended) A method of any one of [claim] claims 75, 76, 78, 80, 82, or 83, wherein A1 in formula (I) is selected from the group consisting of substituted or unsubstituted phenyl, chlorophenyl, fluorophenyl, bromophenyl, iodophenyl, dihalophenyl, nitrophenyl, 4-bromophenyl, 4-chlorophenyl, alkoxyphenyl, dialkoxyphenyl, dialkylphenyl, trialkylphenyl, alkylthiophenyl, trifluoromethylphenyl, acetylphenyl, sulfamoylphenyl, biphenyl, cyclohexylphenyl, phenyloxyphenyl, dialkylaminophenyl, alkylbromophenyl, alkylchlorophenyl, alkylfluorophenyl, trifluoromethylchlorophenyl, trifluoromethylbromophenyl, trifluorophenyl, (trifluoromethyl)thiophenyl, alkoxybiphenyl, hydroxyphenyl, hydroxyalkylphenyl, 4-amino(imino)methylphenyl and (1,4'-bipiperidin-1'-ylcarbonyl)phenyl.

94. (Previously presented) The method of claim 93, wherein A1 in formula (I) is 4-bromophenyl.

95. (Previously presented) The method of claim 93, wherein A_1 in formula (I) is trifluoromethylchlorophenyl.

96. (Currently amended) A method of any one of [claim] claims 75, 76, 78, 80, 82, or 83, wherein A_2 in formula (I) is selected from the group consisting of substituted or unsubstituted phenyl, pyridyl, pyrimidinyl, thiazolyl, indolyl, imidazolyl, oxadiazolyl, tetrazolyl, pyrazinyl, triazolyl, thiophenyl, furanyl, quinolinyl, purinyl, naphthyl, benzothiazolyl, benzopyridyl and benzoimidazolyl.

97. (Previously presented) The method of claim 96, wherein A_2 in formula (I) is pyridyl.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

98. (Previously presented) The method of claim 96, wherein A_2 in formula (I) is



99. (Currently amended) A method of any one of [claim] claims 75, 76, 78, 80, 82, or 83, wherein R_1 is taken together with R_2 in formula (I) to form a substituted or unsubstituted C_{3-8} heterocycloalkyl or C_{3-14} heteroaryl group.

100. (Currently amended) A method of any one of [claim] claims 75, 76, 78, 80, 82, or 83, wherein R_1 is taken together with R_2 in formula (I) to form a group selected from substituted or unsubstituted phenyl, pyridyl, pyrimidinyl, thiazolyl, indolyl, imidazolyl, oxadiazolyl, tetrazolyl, pyrazinyl, triazolyl, thiophenyl, furanyl, quinolinyl, purinyl, naphthyl, benzothiazolyl, benzopyridyl and benzoimidazolyl.

101. (Currently amended) A method of any one of [claim] claims 75, 76, 78, 80, 82, or 83, wherein R_1 is taken together with R_2 in formula (I) to form a substituted or unsubstituted imidazolyl group.

102. (Previously presented) The method of claim 100, wherein the imidazolyl group is substituted with a halo C_{1-6} alkyl group.

103. (Previously presented) The method of claim 100, wherein the imidazolyl group is substituted with a trifluoromethyl group.

104. (Currently amended) A method of any one of [claim] claims 75, 76, 78, 80, 82, or 83, wherein R_3 in formula (I) is hydrogen.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS[PLLC]
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

105. (Currently amended) A method of any one of [claim] claims 75, 76, 78, 80, 82, or 83, wherein R_4 in formula (I) is hydrogen.

106. (Currently amended) A method of any one of [claim] claims 75, 76, 78, 80, 82, or 83, wherein R_5 and R_6 in formula (I) are independently selected from hydrogen and methyl.

107. (Canceled)

108. (Previously presented) The method of claim 75, wherein the cancer is melanoma.

109. (Previously presented) The method of claim 75, wherein the cancer is a carcinoma of the lungs, pancreas, thyroid, bladder or colon.

110. (Previously presented) The method of claim 75, wherein the cancer is myeloid leukemia.

111. (Previously presented) The method of claim 75, wherein the cancer is villous colon adenoma.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100